Cytokinetics (CYTK) news

Cytokinetics shares up 1.4% premarket after co presents new late-stage data for heart drug at European Society of Cardiology

Cytokinetics, Incorporated (Nasdaq: CYTK) reported a 1.4% increase in premarket trading following the presentation of late-stage clinical data for its heart drug, aficamten, at the European Society of Cardiology. The company announced positive topline results from the ACACIA-HCM trial, a pivotal…

Cytokinetics announces positive results from Acacia-HCM

Cytokinetics - seeks injunction against litigation or infringement claims on Myqorzo(aficamten) - SEC filing

Cytokinetics - Demands trial by jury on all triable issues - SEC filing

Cytokinetics - files complaint against Bristol-Myers Squibb and Myokardia - SEC filing

Cytokinetics Inc. has filed a complaint with the U.S. Securities and Exchange Commission (SEC) against Bristol-Myers Squibb Company and Myokardia Inc., alleging violations related to financial disclosures and business practices. The complaint, detailed in a recent SEC filing, centers on alleged…